Hims's Strategy with Copycat GLP-1 Drugs Faces New Challenges

Hims's Entry into the GLP-1 Market

• 💡 Hims, a telehealth company founded in 2017, expanded its offerings beyond ED and hair loss treatments to include weight-loss drugs.
• 🎯 This expansion was driven by the shortage of brand-name GLP-1 drugs like Ozempic and Wegovy, allowing companies like Hims to offer compounded versions.
• 🚀 Hims announced its copycat GLP-1 version in May 2024, pricing it at $199 per month and seeing its stock spike significantly.

The Role of Compounding Pharmacies

• 🔬 Hims leveraged its ownership of two compounding pharmacies to produce these copycat drugs at a lower cost.
• ⚠️ Compounded drugs are not approved by the FDA for safety and efficacy in the same way as commercially available products, allowing for lower pricing.
• 💰 In Q4 2024, GLP-1 drugs reportedly made up 30% of Hims's revenue, highlighting their strategic importance.

FDA Announcement and Shifting Strategy

• 📉 In February 2025, the FDA announced the end of the GLP-1 shortage, impacting Hims's strategy and causing investor concern.
• 🔄 Hims pivoted by focusing on personalization of drugs (e.g., lower doses, added vitamins) to differentiate them from commercially available options.
• 🤝 Hims entered a partnership with Novo Nordisk, the maker of Ozempic and Wegovy, to offer their drugs at a discount, but this partnership abruptly collapsed within two months.

Market Challenges and Future Outlook

• 📈 Following the partnership's failure and missing Wall Street estimates, investors question Hims's ability to maintain sales targets.
• ⚖️ There is a polarizing debate regarding the legality and ethics of compounded drugs, with drug makers like Novo Nordisk and Eli Lilly opposing them.
• 🌐 Despite challenges, Hims aims to expand globally and has changed the pharmaceutical market by making drugs more accessible, a strategy now being emulated by major drug manufacturers.